The use of claims databases for outcomes research: Rationale, challenges, and strategies

被引:137
作者
Motheral, BR [1 ]
Fairman, KA [1 ]
机构
[1] EXPRESS SCRIPTS INC, OUTCOMES RES, MARYLAND HTS, MO USA
关键词
claims database research; outcomes research;
D O I
10.1016/S0149-2918(97)80122-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Health care payers and policy makers need information about the cost and effectiveness of medical treatments, While randomized controlled trials historically are the primary source of medical information, they are expensive and labor-intensive, and often have limited utility for answering questions about ''real-world'' patient populations. These problems have led to an increasing reliance on claims database research in making policy decisions about treatment options. However, both researchers and decision makers should recognize the limitations and unique features of claims databases. Recommendations for avoiding or minimizing threats to internal validity, construct validity, and external validity are: (1) use of a study design that includes comparisons; (2) ensuring that the study design and conclusions are consistent with the database; (3) a priori conceptual modeling of the research question; (4) use of appropriate constructs; (5) explicit examination of alternative explanations for study findings; (6) sensitivity analyses of key assumptions; (7) awareness of the distinction between statistical and practical significance of findings; (8) generalization only when appropriate; and (9) reporting of relevant in formation, Given that any study design or data source has limitations, we hope that this paper will encourage a philosophy of methodological pluralism in outcomes research. Awareness and accurate reporting of validity issues will strengthen and extend the information resources currently available to decision makers.
引用
收藏
页码:346 / 366
页数:21
相关论文
共 76 条
  • [51] AN APPROACH TO SEVERAL PROBLEMS IN USING LARGE DATABASES FOR POPULATION-BASED CASE-CONTROL STUDIES OF THE THERAPEUTIC EFFICACY AND SAFETY OF ANTIHYPERTENSIVE MEDICINES
    PSATY, BM
    KOEPSELL, TD
    SISCOVICK, D
    WAHL, P
    LOGERFO, JP
    INUI, TS
    WAGNER, EH
    [J]. STATISTICS IN MEDICINE, 1991, 10 (04) : 653 - 662
  • [52] THE RELEVANCE OF SEARCHING FOR EFFECTS UNDER A CLINICAL-TRIAL LAMPPOST - A KEY ISSUE
    RITTENHOUSE, BE
    [J]. MEDICAL DECISION MAKING, 1995, 15 (04) : 348 - 357
  • [53] ROMANO PS, 1992, AHCPR PUB, P57
  • [54] DISCUSSING HIDDEN BIAS IN OBSERVATIONAL STUDIES
    ROSENBAUM, PR
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (11) : 901 - 905
  • [55] Rost K, 1994, Arch Fam Med, V3, P333, DOI 10.1001/archfami.3.4.333
  • [56] *RW JOHNS FDN, 1995, WORK LARG INS DAT AV
  • [57] SCLAR DA, 1994, CLIN THER, V16, P715
  • [58] Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization
    Sclar, DA
    Robison, LM
    Skaer, TL
    Galin, RS
    Legg, RF
    Nemec, NL
    Hughes, TE
    Buesching, DP
    Morgan, M
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1995, 23 (06) : 395 - 412
  • [59] SCLAR DA, 1991, J RES PHARM EC, V3, P75
  • [60] COST-EFFECTIVENESS COMPARISONS USING REAL-WORLD RANDOMIZED TRIALS - THE CASE OF NEW ANTIDEPRESSANT DRUGS
    SIMON, G
    WAGNER, E
    VONKORFF, M
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (03) : 363 - 373